{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T16:24:47Z","timestamp":1756311887447},"reference-count":25,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.nano.2011.11.006","type":"journal-article","created":{"date-parts":[[2011,11,18]],"date-time":"2011-11-18T06:06:55Z","timestamp":1321596415000},"page":"131-135","source":"Crossref","is-referenced-by-count":7,"title":["HPV infections: Can they be eradicated using nanotechnology?"],"prefix":"10.1016","volume":"8","author":[{"given":"Marianna","family":"Foldvari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 3","key":"10.1016\/j.nano.2011.11.006_bb0005","first-page":"S3\/52","article-title":"Chapter 6: Epidemiology and transmission dynamics of genital HPV infection","volume":"24","author":"Burchell","year":"2006","journal-title":"Vaccine"},{"issue":"Suppl 3","key":"10.1016\/j.nano.2011.11.006_bb0010","first-page":"S3\/193","article-title":"Chapter 23: international standard reagents for harmonization of HPV serology and DNA assays\u2013an update","volume":"24","author":"Pagliusi","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.nano.2011.11.006_bb0015","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/canjclin.57.1.7","article-title":"American Cancer Society guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors","volume":"57","author":"Saslow","year":"2007","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.nano.2011.11.006_bb0020","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/jmv.21733","article-title":"Distribution of human papillomavirus types in the anogenital tract of females and males","volume":"82","author":"Barzon","year":"2010","journal-title":"J Med Virol"},{"key":"10.1016\/j.nano.2011.11.006_bb0025","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.ygyno.2010.04.004","article-title":"Current understanding of the mechanism of HPV infection","volume":"118","author":"Schiller","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.nano.2011.11.006_bb0030","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrc2050","article-title":"The natural history of cervical HPV infection: unresolved issues","volume":"7","author":"Woodman","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.nano.2011.11.006_bb0035","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","article-title":"Human papillomavirus is a necessary cause of invasive cervical cancer worldwide","volume":"189","author":"Walboomers","year":"1999","journal-title":"J Pathol"},{"key":"10.1016\/j.nano.2011.11.006_bb0040","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nrc798","article-title":"Papillomaviruses and cancer: from basic studies to clinical application","volume":"2","author":"zur Hausen","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.nano.2011.11.006_bb0045","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.virol.2008.11.046","article-title":"Papillomaviruses in the causation of human cancers - a brief historical account","volume":"384","author":"zur Hausen","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.nano.2011.11.006_bb0050","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1097\/00000478-198110000-00008","article-title":"Human papillomavirus (HPV) in condylomatous lesions of cervix","volume":"5","author":"Ferenczy","year":"1981","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.nano.2011.11.006_bb0055","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ajog.2007.07.047","article-title":"2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests","volume":"197","author":"Wright","year":"2007","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.nano.2011.11.006_bb0060","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejogrb.2006.07.048","article-title":"New paradigm for prevention of cervical cancer","volume":"130","author":"Kaufmannand","year":"2007","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.nano.2011.11.006_bb0065","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/sj.clpt.6100055","article-title":"Gardasil: prophylactic human papillomavirus vaccine development\u2013from bench top to bed-side","volume":"81","author":"Shi","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.nano.2011.11.006_bb0070","first-page":"626","article-title":"Centers for Disease Control and Prevention (CDC). FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP)","volume":"59","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.nano.2011.11.006_bb0075","doi-asserted-by":"crossref","first-page":"407","DOI":"10.4161\/hv.6.5.11023","article-title":"Molecular and structural characterization of the L1 virus-like particles that are used as vaccine antigens in Cervarix, the AS04-adjuvanted HPV-16 and -18 cervical cancer vaccine","volume":"6","author":"Deschuyteneer","year":"2010","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.nano.2011.11.006_bb0080","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S1097-2765(00)80449-9","article-title":"Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16","volume":"5","author":"Chen","year":"2000","journal-title":"Mol Cell"},{"key":"10.1016\/j.nano.2011.11.006_bb0085","doi-asserted-by":"crossref","first-page":"12180","DOI":"10.1073\/pnas.89.24.12180","article-title":"Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic","volume":"89","author":"Kirnbauer","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nano.2011.11.006_bb0090","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1542\/peds.2010-0812","article-title":"Adherence to the HPV vaccine dosing intervals and factors associated with completion of 3 doses","volume":"127","author":"Widdice","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.nano.2011.11.006_bb0095","first-page":"39","article-title":"Reducing the rate of cervical cancer: ethical challenges in public health","volume":"21","author":"Beard","year":"2010","journal-title":"J Natl Black Nurses Assoc"},{"key":"10.1016\/j.nano.2011.11.006_bb0100","first-page":"1018","article-title":"Centers for Disease Control and Prevention (CDC). National, state, and local area vaccination coverage among adolescents aged 13-17 years \u2014 United States, 2009","volume":"59","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.nano.2011.11.006_bb0105","first-page":"630","article-title":"Centers for Disease Control and Prevention (CDC). FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP)","volume":"59","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.nano.2011.11.006_bb0110","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2174\/157339410791202583","article-title":"HPV and therapeutic vaccines: Where are we in 2010?","volume":"6","author":"Ma","year":"2010","journal-title":"Curr Cancer Ther Rev"},{"key":"10.1016\/j.nano.2011.11.006_bb0115","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2174\/156720111795256129","article-title":"Biphasic vesicles for topical delivery of interferon alpha in human volunteers and treatment of patients with human papillomavirus infections","volume":"8","author":"Foldvari","year":"2011","journal-title":"Curr Drug Deliv"},{"key":"10.1016\/j.nano.2011.11.006_bb0120","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1166\/jbn.2010.1151","article-title":"Biphasic vesicles: a novel topical drug delivery system","volume":"6","author":"Foldvari","year":"2010","journal-title":"J Biomed Nanotechnol"},{"key":"10.1016\/j.nano.2011.11.006_bb0125","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1021\/mp900283x","article-title":"Topical delivery of interferon alpha by biphasic vesicles: evidence for a novel nanopathway across the stratum corneum","volume":"7","author":"Foldvari","year":"2010","journal-title":"Mol Pharm"}],"container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963411005260?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963411005260?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,28]],"date-time":"2018-11-28T06:20:31Z","timestamp":1543386031000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1549963411005260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S1549963411005260"],"URL":"https:\/\/doi.org\/10.1016\/j.nano.2011.11.006","relation":{},"ISSN":["1549-9634"],"issn-type":[{"value":"1549-9634","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]}}}